Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A 21-year-old male managed to control his hair loss using Nizoral, RU58841, and finasteride, but experienced increased scalp itchiness after starting creatine, which subsided upon stopping creatine. Users shared mixed experiences on whether creatine affects hair loss, with some reporting negative effects and others seeing no change or defending its benefits.

Creatine might increase hair loss due to increased DHT sensitivity, but evidence is mostly anecdotal. The user is using oral minoxidil for hair loss and is cautious about starting creatine.

Excessive use of Nizoral can lead to dry, brittle hair and is not recommended more than 1-2 times a week. Users suggest using conditioner to mitigate dryness and note that Nizoral is more effective for treating fungal issues rather than regrowing hair.

Hair loss treatments discussed include dermarolling, minoxidil, finasteride, and RU58841. Some users find dermarolling sad, while others mention the complexity of biological systems and limited research funding for hair loss.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

The conversation discusses combining topical and oral finasteride to address hair thinning, with concerns about safety and effectiveness. Users also mention alternatives like dutasteride and minoxidil, and the potential risks of topical treatments during pregnancy.

Stemson Therapeutics has shut down, disappointing those seeking a hair loss cure. Current treatments like minoxidil, finasteride, and dutasteride are discussed, with some users experiencing side effects and exploring alternatives like PP405.

Oral minoxidil may cause facial bloating and dark circles, making some users feel they look older. Some consider reducing the dosage or switching treatments due to these side effects.

A 25-year-old man with hair loss from bleach damage is using oral minoxidil and considering adding Dutasteride for better regrowth and prevention. He seeks advice on Dutasteride's effectiveness and potential benefits over finasteride, and is also curious about RU58841.

RT1640, a combination of cyclosporin A, minoxidil, and RT175, is discussed as a potential treatment for hair regrowth and repigmentation. The unique formulation aims to enhance hair follicle growth and restore hair pigment without the negative side effects of immunosuppressants.

The conversation discusses the user's experience with depression after starting Dutasteride for hair loss, considering whether to lower the dose or try supplements like nootropics. Another user suggests that stopping Dutasteride might not resolve the depression and warns against attributing all issues to the medication.

Pumpkin seed oil and saw palmetto are discussed as natural DHT blockers with potentially fewer side effects than finasteride. Users share experiences with these treatments, noting concerns about mental health and side effects from finasteride.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.

Clascoterone results are anticipated to be released in fall 2026, possibly at the EADV conference. Users express skepticism and humor about the release date.

A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.

Temporal peaks are crucial for a natural-looking hair transplant, but they are challenging to achieve due to the need for precise angles and appropriate hair thickness. Many users emphasize the importance of finding a skilled surgeon and using finasteride to maintain hairline stability.

A 22-year-old male uses dutasteride, a serum with 10% minoxidil and 0.5% finasteride, and microneedling for diffuse androgenetic alopecia. Progress pictures show changes from July 2025 to February 2026.

A user in their 20s with androgenetic alopecia is experiencing heavy hair shedding after starting dutasteride and oral minoxidil, with concerns about scalp sensitivity and low vitamin D. They plan to consult a dermatologist for further evaluation, while others in the conversation share similar experiences with shedding after starting dutasteride.

A 25-year-old male experienced significant hair loss due to telogen effluvium and androgenetic alopecia. He began using finasteride, minoxidil, and vitamins, seeing some regrowth but remains worried about hair density.

The user experienced temple recession, shedding, and acne while on 0.5mg dutasteride, 1.25mg finasteride every other day, and 5mg oral minoxidil daily. They are considering switching treatments due to worsening symptoms and are contemplating using a topical anti-androgen like RU58841.

The user experienced aggressive hair loss despite using oral finasteride and minoxidil, with additional issues like dandruff and eyebrow hair loss. They are considering switching to oral minoxidil and dutasteride due to scalp inflammation and lack of improvement.

The conversation discusses androgenic alopecia (AGA) and its treatments, focusing on finasteride, minoxidil, and ketoconazole shampoo. Finasteride is recommended as essential for preventing further hair loss.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

A 19-year-old male is experiencing accelerated hair recession after two months on oral Dutasteride, despite no noticeable shedding, while also using topical Minoxidil and Finasteride. He is unsure if the treatment is effective and is unable to access RU58841.

The user experienced significant hair regrowth using finasteride, minoxidil, and microneedling but later faced rapid thinning despite consistent treatment. They plan to switch from finasteride to dutasteride and consider oral minoxidil if the situation doesn't improve.

The user has been taking 0.5 mg of finasteride daily for two months and is experiencing testicular ache, which they believe might be related to the medication. They plan to continue the treatment for a few more months despite the discomfort, hoping the side effects will subside.

Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.

The user experienced a sudden and severe hair loss after 1.5 years of successful treatment with finasteride and minoxidil. They plan to check their thyroid and vitamin D levels as potential causes.